2000
DOI: 10.1007/bf02830516
|View full text |Cite
|
Sign up to set email alerts
|

Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
37
0

Year Published

2005
2005
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 38 publications
(38 citation statements)
references
References 14 publications
1
37
0
Order By: Relevance
“…All of the following methods were previously validated for dogs (Ravivarapu et al 2000;Gallelli et al 2010;Cabrera Blatter et al 2011;Ithurralde et al 2013).…”
Section: Animalsmentioning
confidence: 99%
“…All of the following methods were previously validated for dogs (Ravivarapu et al 2000;Gallelli et al 2010;Cabrera Blatter et al 2011;Ithurralde et al 2013).…”
Section: Animalsmentioning
confidence: 99%
“…The implant formulation consisted of 45% w/w 75/25 poly(DL-lactide-co-glycolide) (PLG) polymer having an intrinsic viscosity of 0.20 dl/g dissolved in N-methyl-2-pyrrolidone (NMP) and containing 6% w/w leuprolide in the polymer solution. This formulation was designed to release the drug for a period of 3-4 mo after subcutaneous injection (Ravivarapu et al, 2000).…”
Section: Introductionmentioning
confidence: 99%
“…N-methyl pyrrolidone is a relatively nontoxic solvent commonly used for solubilization, 20 transdermal drug delivery, 21 and in situ gel formulation. 22 A specific amount (5 mg) of buprenorphine HCl was added to the polymer solution and mixed thoroughly for 60 seconds using a vibrating mixer (Vibra Model 231, Fisher Scientific, Pittsburgh, PA). The resultant drug/polymer solution was transformed into a gel by injecting it into a Spectra-Por dialysis bag containing 1.5 mL of the dissolution medium (Figure 1).…”
Section: Preparation Of In Situ Gelmentioning
confidence: 99%